Peter Rossing1,2, Ellen Burgess3, Rajiv Agarwal4, Stefan D Anker5, Gerasimos Filippatos6, Bertram Pitt7, Luis M Ruilope8,9,10, Pieter Gillard11, Richard J MacIsaac12, Julio Wainstein13,14, Amer Joseph15, Meike Brinker15, Lothar Roessig15, Charlie Scott16, George L Bakris17. 1. Steno Diabetes Center Copenhagen, Herlev, Denmark. 2. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. 3. Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 4. Richard L. Roudebush VA Medical Center and Indiana University, Indianapolis, IN. 5. Department of Cardiology, and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany. 6. National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Athens, Greece. 7. Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI. 8. Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain. 9. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Hospital Universitario 12 de Octubre, Madrid, Spain. 10. Faculty of Sport Sciences, European University of Madrid, Madrid, Spain. 11. Department of Endocrinology, University Hospital Leuven - Katholieke Universiteit Leuven, Leuven, Belgium. 12. Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne and University of Melbourne, Melbourne, Victoria, Australia. 13. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 14. Diabetes Unit, Edith Wolfson Medical Center, Holon, Israel. 15. Cardiology and Nephrology Clinical Development, Bayer AG, Berlin, Germany. 16. Data Science and Analytics, Bayer PLC, Reading, U.K. 17. Department of Medicine, University of Chicago Medicine, Chicago, IL.
Abstract
OBJECTIVE: Finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial. We explored whether baseline HbA1c level and insulin treatment influenced outcomes. RESEARCH DESIGN AND METHODS: Patients with T2D, urine albumin-to-creatinine ratio (UACR) of 30-5,000 mg/g, estimated glomerular filtration rate (eGFR) of 25 to <75 mL/min/1.73 m2, and treated with optimized renin-angiotensin system blockade were randomly assigned to receive finerenone or placebo. Efficacy outcomes included kidney (kidney failure, sustained decrease ≥40% in eGFR from baseline, or renal death) and cardiovascular (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) composite endpoints. Patients were analyzed by baseline insulin use and by baseline HbA1c <7.5% (58 mmol/mol) or ≥7.5%. RESULTS: Of 5,674 patients, 3,637 (64.1%) received insulin at baseline. Overall, 5,663 patients were included in the analysis for HbA1c; 2,794 (49.3%) had baseline HbA1c <7.5% (58 mmol/mol). Finerenone significantly reduced risk of the kidney composite outcome independent of baseline HbA1c level and insulin use (Pinteraction = 0.41 and 0.56, respectively). Cardiovascular composite outcome incidence was reduced with finerenone irrespective of baseline HbA1c level and insulin use (Pinteraction = 0.70 and 0.33, respectively). Although baseline HbA1c level did not affect kidney event risk, cardiovascular risk increased with higher HbA1c level. UACR reduction was consistent across subgroups. Adverse events were similar between groups regardless of baseline HbA1c level and insulin use; few finerenone-treated patients discontinued treatment because of hyperkalemia. CONCLUSIONS: Finerenone reduces kidney and cardiovascular outcome risk in patients with CKD and T2D, and risks appear consistent irrespective of HbA1c levels or insulin use.
OBJECTIVE: Finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial. We explored whether baseline HbA1c level and insulin treatment influenced outcomes. RESEARCH DESIGN AND METHODS: Patients with T2D, urine albumin-to-creatinine ratio (UACR) of 30-5,000 mg/g, estimated glomerular filtration rate (eGFR) of 25 to <75 mL/min/1.73 m2, and treated with optimized renin-angiotensin system blockade were randomly assigned to receive finerenone or placebo. Efficacy outcomes included kidney (kidney failure, sustained decrease ≥40% in eGFR from baseline, or renal death) and cardiovascular (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) composite endpoints. Patients were analyzed by baseline insulin use and by baseline HbA1c <7.5% (58 mmol/mol) or ≥7.5%. RESULTS: Of 5,674 patients, 3,637 (64.1%) received insulin at baseline. Overall, 5,663 patients were included in the analysis for HbA1c; 2,794 (49.3%) had baseline HbA1c <7.5% (58 mmol/mol). Finerenone significantly reduced risk of the kidney composite outcome independent of baseline HbA1c level and insulin use (Pinteraction = 0.41 and 0.56, respectively). Cardiovascular composite outcome incidence was reduced with finerenone irrespective of baseline HbA1c level and insulin use (Pinteraction = 0.70 and 0.33, respectively). Although baseline HbA1c level did not affect kidney event risk, cardiovascular risk increased with higher HbA1c level. UACR reduction was consistent across subgroups. Adverse events were similar between groups regardless of baseline HbA1c level and insulin use; few finerenone-treated patients discontinued treatment because of hyperkalemia. CONCLUSIONS: Finerenone reduces kidney and cardiovascular outcome risk in patients with CKD and T2D, and risks appear consistent irrespective of HbA1c levels or insulin use.
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman Journal: N Engl J Med Date: 2016-06-14 Impact factor: 91.245
Authors: Vlado Perkovic; Hiddo Lambers Heerspink; John Chalmers; Mark Woodward; Min Jun; Qiang Li; Stephen MacMahon; Mark E Cooper; Pavel Hamet; Michel Marre; Carl Erik Mogensen; Neil Poulter; Giuseppe Mancia; Alan Cass; Anushka Patel; Sophia Zoungas Journal: Kidney Int Date: 2013-01-09 Impact factor: 10.612
Authors: Peter Rossing; Rajiv Agarwal; Stefan D Anker; Gerasimos Filippatos; Bertram Pitt; Luis M Ruilope; Aslam Amod; Michel Marre; Amer Joseph; Andrea Lage; Charlie Scott; George L Bakris Journal: Diabetes Obes Metab Date: 2021-10-11 Impact factor: 6.408
Authors: Sandra Korol; Fannie Mottet; Sylvie Perreault; William L Baker; Michel White; Simon de Denus Journal: Medicine (Baltimore) Date: 2017-12 Impact factor: 1.817